Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITO36: Trabectedin and PLD in Recurrent Ovarian Cancer
NCT04887961Phase 2Unknown
- Sponsor
- Policlinico Gemelli
- Start
- Oct 2020
- Primary completion
- Apr 2022
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trabectedin, doxorubicin in ovarian cancer, sponsored by Policlinico Gemelli. Status: unknown.
02
Drugs
trabectedindoxorubicin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04887961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04887961.